-DOCSTART- -X- O
PURPOSE -X- _ O
: -X- _ O
To -X- _ O
determine -X- _ O
the -X- _ O
factors -X- _ O
that -X- _ O
predict -X- _ O
in-hospital -X- _ O
mortality -X- _ O
among -X- _ O
patients -X- _ O
who -X- _ O
require -X- _ O
hospitalization -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
community-acquired -X- _ B-Patient
pneumonia -X- _ I-Patient
( -X- _ I-Patient
CAP -X- _ I-Patient
) -X- _ I-Patient
STUDY -X- _ O
DESIGN -X- _ O
: -X- _ O
Prospective -X- _ O
observational -X- _ O
study -X- _ O
of -X- _ O
all -X- _ O
patients -X- _ O
who -X- _ O
were -X- _ O
admitted -X- _ O
to -X- _ O
six -X- _ O
hospitals -X- _ O
in -X- _ O
Edmonton -X- _ O
, -X- _ O
AL -X- _ O
, -X- _ O
Canada -X- _ O
, -X- _ O
with -X- _ O
a -X- _ O
diagnosis -X- _ O
of -X- _ O
CAP -X- _ O
from -X- _ O
November -X- _ O
15 -X- _ O
, -X- _ O
2000 -X- _ O
, -X- _ O
to -X- _ O
November -X- _ O
14 -X- _ O
, -X- _ O
2002. -X- _ O
Pneumonia -X- _ O
was -X- _ O
defined -X- _ O
as -X- _ O
two -X- _ O
or -X- _ O
more -X- _ O
respiratory -X- _ O
symptoms -X- _ O
and -X- _ O
signs -X- _ O
and -X- _ O
an -X- _ O
opacity -X- _ O
on -X- _ O
a -X- _ O
chest -X- _ O
radiograph -X- _ O
as -X- _ O
interpreted -X- _ O
by -X- _ O
the -X- _ O
attending -X- _ O
physician -X- _ O
RESULTS -X- _ O
: -X- _ O
A -X- _ O
total -X- _ O
of -X- _ O
3,043 -X- _ B-Patient
patients -X- _ I-Patient
were -X- _ O
enrolled -X- _ O
in -X- _ O
the -X- _ O
study -X- _ O
, -X- _ O
246 -X- _ O
of -X- _ O
whom -X- _ O
died -X- _ O
( -X- _ O
8.1 -X- _ O
% -X- _ O
) -X- _ O
. -X- _ O
On -X- _ O
multivariate -X- _ O
analysis -X- _ O
, -X- _ O
increasing -X- _ O
pneumonia -X- _ O
severity -X- _ O
score -X- _ O
, -X- _ O
increasing -X- _ O
age -X- _ O
, -X- _ O
site -X- _ O
of -X- _ O
care -X- _ O
, -X- _ O
consultation -X- _ O
with -X- _ O
a -X- _ O
respirologist -X- _ O
or -X- _ O
infectious -X- _ O
diseases -X- _ O
physician -X- _ O
, -X- _ O
and -X- _ O
functional -X- _ O
status -X- _ O
at -X- _ O
the -X- _ O
time -X- _ O
of -X- _ O
admission -X- _ O
were -X- _ O
all -X- _ O
independently -X- _ O
predictive -X- _ O
of -X- _ O
mortality. -X- _ O
Increasing -X- _ B-Outcome
pneumonia -X- _ I-Outcome
severity -X- _ I-Outcome
risk -X- _ I-Outcome
score -X- _ I-Outcome
, -X- _ I-Outcome
increasing -X- _ I-Outcome
age -X- _ I-Outcome
, -X- _ I-Outcome
site -X- _ I-Outcome
of -X- _ I-Outcome
hospitalization -X- _ I-Outcome
, -X- _ I-Outcome
functional -X- _ I-Outcome
status -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
consultation -X- _ I-Outcome
with -X- _ I-Outcome
an -X- _ I-Outcome
infectious -X- _ I-Outcome
diseases -X- _ I-Outcome
physician -X- _ I-Outcome
or -X- _ I-Outcome
a -X- _ I-Outcome
respirologist -X- _ I-Outcome
were -X- _ I-Outcome
independently -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
both -X- _ I-Outcome
early -X- _ I-Outcome
( -X- _ I-Outcome
< -X- _ I-Outcome
5 -X- _ I-Outcome
days -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
late -X- _ I-Outcome
( -X- _ I-Outcome
â‰¥ -X- _ I-Outcome
5 -X- _ I-Outcome
days -X- _ I-Outcome
) -X- _ I-Outcome
mortality. -X- _ I-Outcome
In -X- _ I-Outcome
contrast -X- _ I-Outcome
, -X- _ I-Outcome
partial -X- _ I-Outcome
or -X- _ I-Outcome
complete -X- _ I-Outcome
use -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
pneumonia -X- _ I-Outcome
pathway -X- _ I-Outcome
was -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
decreased -X- _ I-Outcome
early -X- _ I-Outcome
mortality -X- _ I-Outcome
, -X- _ I-Outcome
but -X- _ I-Outcome
had -X- _ I-Outcome
no -X- _ I-Outcome
effect -X- _ I-Outcome
on -X- _ I-Outcome
late -X- _ I-Outcome
mortality. -X- _ I-Outcome
A -X- _ I-Outcome
low -X- _ I-Outcome
lymphocyte -X- _ I-Outcome
count -X- _ I-Outcome
and -X- _ I-Outcome
a -X- _ I-Outcome
high -X- _ I-Outcome
serum -X- _ I-Outcome
potassium -X- _ I-Outcome
level -X- _ I-Outcome
were -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
early -X- _ I-Outcome
but -X- _ I-Outcome
not -X- _ I-Outcome
with -X- _ I-Outcome
late -X- _ I-Outcome
mortality. -X- _ I-Outcome
The -X- _ I-Outcome
type -X- _ I-Outcome
of -X- _ I-Outcome
antibiotic -X- _ I-Outcome
therapy -X- _ I-Outcome
had -X- _ I-Outcome
an -X- _ I-Outcome
effect -X- _ I-Outcome
on -X- _ I-Outcome
late -X- _ I-Outcome
but -X- _ I-Outcome
not -X- _ I-Outcome
on -X- _ I-Outcome
early -X- _ I-Outcome
mortality -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Functional -X- _ O
status -X- _ O
at -X- _ O
the -X- _ O
time -X- _ O
of -X- _ O
hospital -X- _ O
admission -X- _ O
is -X- _ O
a -X- _ O
powerful -X- _ O
predictor -X- _ O
of -X- _ O
mortality -X- _ O
and -X- _ O
should -X- _ O
be -X- _ O
incorporated -X- _ O
into -X- _ O
any -X- _ O
scores -X- _ O
or -X- _ O
models -X- _ O
that -X- _ O
are -X- _ O
used -X- _ O
to -X- _ O
predict -X- _ O
mortality. -X- _ O
While -X- _ O
there -X- _ O
are -X- _ O
some -X- _ O
common -X- _ O
predictors -X- _ O
of -X- _ O
early -X- _ O
and -X- _ O
late -X- _ O
in-hospital -X- _ O
mortality -X- _ O
, -X- _ O
early -X- _ O
mortality -X- _ O
is -X- _ O
not -X- _ O
affected -X- _ O
by -X- _ O
the -X- _ O
timing -X- _ O
or -X- _ O
type -X- _ O
of -X- _ O
antibiotic -X- _ O
therapy -X- _ O
, -X- _ O
whereas -X- _ O
late -X- _ O
mortality -X- _ O
is -X- _ O
influenced -X- _ O
by -X- _ O
the -X- _ O
type -X- _ O
of -X- _ O
antibiotic -X- _ O
therapy. -X- _ O
Hyperkalemia -X- _ O
and -X- _ O
lymphopenia -X- _ O
are -X- _ O
associated -X- _ O
with -X- _ O
early -X- _ O
mortality -X- _ O

